Citations (44)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
E David Crawford, Whitney Stanton & Divneet Mandair. (2020) Darolutamide: An Evidenced-Based Review of Its Efficacy and Safety in the Treatment of Prostate Cancer. Cancer Management and Research 12, pages 5667-5676.
Read now
Read now
Anupam Batra & Eric Winquist. (2018) Emerging cell cycle inhibitors for treating metastatic castration-resistant prostate cancer. Expert Opinion on Emerging Drugs 23:4, pages 271-282.
Read now
Read now
Gail P Risbridger. (2011) Contemporary approaches to prostate cancer research. Expert Review of Endocrinology & Metabolism 6:3, pages 299-300.
Read now
Read now
Articles from other publishers (41)
Zahraa Saker, Mahdi Rizk & Sanaa Nabha. 2024. Therapy Resistance in Prostate Cancer. Therapy Resistance in Prostate Cancer
57
84
.
Ahmed M. Elshazly & David A. Gewirtz. (2023) Making the Case for Autophagy Inhibition as a Therapeutic Strategy in Combination with Androgen-Targeted Therapies in Prostate Cancer. Cancers 15:20, pages 5029.
Crossref
Crossref
K.M. Biernacka, R. Barker, A. Sewell, A. Bahl & C.M. Perks. (2023) A role for androgen receptor variant 7 in sensitivity to therapy: Involvement of IGFBP-2 and FOXA1. Translational Oncology 34, pages 101698.
Crossref
Crossref
Se Hyo Jeong, Hun Hwan Kim, Min Young Park, Pritam Bhagwan Bhosale, Abuyaseer Abusaliya, Chung Kil Won, Kwang Il Park, Eunhye Kim, Jeong Doo Heo, Hyun Wook Kim, Meejung Ahn, Je Kyung Seong & Gon Sup Kim. (2023) Flavones: The Apoptosis in Prostate Cancer of Three Flavones Selected as Therapeutic Candidate Models. International Journal of Molecular Sciences 24:11, pages 9240.
Crossref
Crossref
Busola Ruth Alabi, Shiqin Liu & Tanya Stoyanova. (2022) Current and emerging therapies for neuroendocrine prostate cancer. Pharmacology & Therapeutics 238, pages 108255.
Crossref
Crossref
Liam King, Nijole Bernaitis, David Christie, Russ Chess-Williams, Donna Sellers, Catherine McDermott, Wendy Dare & Shailendra Anoopkumar-Dukie. (2022) Drivers of Radioresistance in Prostate Cancer. Journal of Clinical Medicine 11:19, pages 5637.
Crossref
Crossref
Francesco Pinto, Francesco Dibitetto, Mauro Ragonese & Pierfrancesco Bassi. (2022) Mechanisms of Resistance to Second-Generation Antiandrogen Therapy for Prostate Cancer: Actual Knowledge and Perspectives. Medical Sciences 10:2, pages 25.
Crossref
Crossref
Meghan A. Rice, Vineet Kumar, Dhanir Tailor, Fernando Jose Garcia-Marques, En-Chi Hsu, Shiqin Liu, Abel Bermudez, Vijayalakshmi Kanchustambham, Vishnu Shankar, Zintis Inde, Busola Ruth Alabi, Arvind Muruganantham, Michelle Shen, Mallesh Pandrala, Rosalie Nolley, Merve Aslan, Ali Ghoochani, Arushi Agarwal, Mark Buckup, Manoj Kumar, Catherine C. Going, Donna M. Peehl, Scott J. Dixon, Richard N. Zare, James D. Brooks, Sharon J. Pitteri, Sanjay V. Malhotra & Tanya Stoyanova. (2022) SU086, an inhibitor of HSP90, impairs glycolysis and represents a treatment strategy for advanced prostate cancer. Cell Reports Medicine 3:2, pages 100502.
Crossref
Crossref
Abdulrahman a Babkoor, Yazeed Aljabri, Ahmad Alzubaidi, Rayan Alhazmi, Zeyad Alsaedi, Faris Alghamdi, Tariq Tamim, Ahmad Aldagani, Irfan Seddiqi & Emad Tashkandi. (2022) Risk of Fatigue and Anemia in Patients With Prostate Cancer Treated With Novel Oral Anti-androgens: A Meta-Analysis of Randomized Controlled Trials. Cureus.
Crossref
Crossref
ZL Zeng, Qingyun Zhu, Zhibo Zhao, Xuyu Zu & Jianghua Liu. (2021) Magic and mystery of microRNA‐32. Journal of Cellular and Molecular Medicine 25:18, pages 8588-8601.
Crossref
Crossref
Hannes Neuwirt, Jan Bouchal, Gvantsa Kharaishvili, Christian Ploner, Karin Jöhrer, Florian Pitterl, Anja Weber, Helmut Klocker & Iris E. Eder. (2020) Cancer-associated fibroblasts promote prostate tumor growth and progression through upregulation of cholesterol and steroid biosynthesis. Cell Communication and Signaling 18:1.
Crossref
Crossref
Mohamed E. Elsesy, Su Jung Oh-Hohenhorst, Anastassia Löser, Christoph Oing, Sally Mutiara, Sabrina Köcher, Stefanie Meien, Alexandra Zielinski, Susanne Burdak-Rothkamm, Derya Tilki, Hartwig Huland, Rudolf Schwarz, Cordula Petersen, Carsten Bokemeyer, Kai Rothkamm & Wael Y. Mansour. (2020) Second-Generation Antiandrogen Therapy Radiosensitizes Prostate Cancer Regardless of Castration State through Inhibition of DNA Double Strand Break Repair. Cancers 12:9, pages 2467.
Crossref
Crossref
Sirin Saranyutanon, Sanjeev Kumar Srivastava, Sachin Pai, Seema Singh & Ajay Pratap Singh. (2019) Therapies Targeted to Androgen Receptor Signaling Axis in Prostate Cancer: Progress, Challenges, and Hope. Cancers 12:1, pages 51.
Crossref
Crossref
Meghan A. Rice, Sanjay V. Malhotra & Tanya Stoyanova. (2019) Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer. Frontiers in Oncology 9.
Crossref
Crossref
Aashi P. Chaturvedi & Scott M. Dehm. 2019. Prostate Cancer. Prostate Cancer
333
350
.
Chellappagounder Thangavel, Maryna Perepelyuk, Ettickan Boopathi, Yi Liu, Steven Polischak, Deepak A. Deshpande, Khadija Rafiq, Adam P. Dicker, Karen E. Knudsen, Sunday A. Shoyele & Robert B. Den. (2018) Improvement in Therapeutic Efficacy and Reduction in Cellular Toxicity: Introduction of a Novel Anti-PSMA-Conjugated Hybrid Antiandrogen Nanoparticle. Molecular Pharmaceutics 15:5, pages 1778-1790.
Crossref
Crossref
Leena Latonen, Mauro Scaravilli, Andrew Gillen, Samuli Hartikainen, Fu-Ping Zhang, Pekka Ruusuvuori, Paula Kujala, Matti Poutanen & Tapio Visakorpi. (2017) In Vivo Expression of miR-32 Induces Proliferation in Prostate Epithelium. The American Journal of Pathology 187:11, pages 2546-2557.
Crossref
Crossref
C McNair, A Urbanucci, C E S Comstock, M A Augello, J F Goodwin, R Launchbury, S G Zhao, M J Schiewer, A Ertel, J Karnes, E Davicioni, L Wang, Q Wang, I G Mills, F Y Feng, W Li, J S Carroll & K E Knudsen. (2016) Cell cycle-coupled expansion of AR activity promotes cancer progression. Oncogene 36:12, pages 1655-1668.
Crossref
Crossref
Yuning Liao, Ningning Liu, Xianliang Hua, Jianyu Cai, Xiaohong Xia, Xuejun Wang, Hongbiao Huang & Jinbao Liu. (2017) Proteasome-associated deubiquitinase ubiquitin-specific protease 14 regulates prostate cancer proliferation by deubiquitinating and stabilizing androgen receptor. Cell Death & Disease 8:2, pages e2585-e2585.
Crossref
Crossref
Felix J. Kim & Christina M. Maher. 2017. Sigma Proteins: Evolution of the Concept of Sigma Receptors. Sigma Proteins: Evolution of the Concept of Sigma Receptors
237
308
.
Leena Latonen, Katri A. Leinonen, Teemu Grönlund, Robert L. Vessella, Teuvo L. J. Tammela, Outi R. Saramäki & Tapio Visakorpi. (2016) Amplification of the 9p13.3 chromosomal region in prostate cancer. Genes, Chromosomes and Cancer 55:8, pages 617-625.
Crossref
Crossref
Jack Schalken & John M. Fitzpatrick. (2016) Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer. BJU International 117:2, pages 215-225.
Crossref
Crossref
Neal D Shore, Simon Chowdhury, Arnauld Villers, Laurence Klotz, D Robert Siemens, De Phung, Steve van Os, Nahla Hasabou, Fong Wang, Suman Bhattacharya & Axel Heidenreich. (2016) Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. The Lancet Oncology 17:2, pages 153-163.
Crossref
Crossref
A. C. GoreV. A. ChappellS. E. FentonJ. A. FlawsA. NadalG. S. PrinsJ. ToppariR. T. Zoeller. (2015) EDC-2: The Endocrine Society's Second Scientific Statement on Endocrine-Disrupting Chemicals. Endocrine Reviews 36:6, pages E1-E150.
Crossref
Crossref
Kirsi M. Kaukoniemi, Hanna E. Rauhala, Mauro Scaravilli, Leena Latonen, Matti Annala, Robert L. Vessella, Matti Nykter, Teuvo L. J. Tammela & Tapio Visakorpi. (2015) Epigenetically altered miR‐193b targets cyclin D1 in prostate cancer. Cancer Medicine 4:9, pages 1417-1425.
Crossref
Crossref
Mengmeng Liang, Helty Adisetiyo, Xiuqing Liu, Ren Liu, Parkash Gill, Pradip Roy-Burman, Jeremy O. Jones & David J. Mulholland. (2015) Identification of Androgen Receptor Splice Variants in the Pten Deficient Murine Prostate Cancer Model. PLOS ONE 10:7, pages e0131232.
Crossref
Crossref
Jake Higgins, Michele Brogley, Nallasivam Palanisamy, Rohit Mehra, Michael M. Ittmann, Jun Z. Li, Scott A. Tomlins & Diane M. Robins. (2015) Interaction of the Androgen Receptor, ETV1, and PTEN Pathways in Mouse Prostate Varies with Pathological Stage and Predicts Cancer Progression. Hormones and Cancer 6:2-3, pages 67-86.
Crossref
Crossref
Gail S. Prins & Mark Lindgren. 2015. Knobil and Neill's Physiology of Reproduction. Knobil and Neill's Physiology of Reproduction
773
804
.
Karen E. Knudsen. (2014) Hormone Whodunit: Clues for Solving the Case of Intratumor Androgen Production. Clinical Cancer Research 20:21, pages 5343-5345.
Crossref
Crossref
Michael A. Augello, Robert B. Den & Karen E. Knudsen. (2014) AR function in promoting metastatic prostate cancer. Cancer and Metastasis Reviews 33:2-3, pages 399-411.
Crossref
Crossref
A Shatnawi, J D Norris, C Chaveroux, J S Jasper, A B Sherk, D P McDonnell & V Giguère. (2013) ELF3 is a repressor of androgen receptor action in prostate cancer cells. Oncogene 33:7, pages 862-871.
Crossref
Crossref
Elaine T. Lam & L. Michael Glodé. (2013) Neoadjuvant and Adjuvant Hormonal and Chemotherapy for Prostate Cancer. Hematology/Oncology Clinics of North America 27:6, pages 1189-1204.
Crossref
Crossref
C E S Comstock, M A Augello, J F Goodwin, R de Leeuw, M J Schiewer, W F OstranderJrJr, R A Burkhart, A K McClendon, P A McCue, E J Trabulsi, C D Lallas, L G Gomella, M M Centenera, J R Brody, L M Butler, W D Tilley & K E Knudsen. (2013) Targeting cell cycle and hormone receptor pathways in cancer. Oncogene 32:48, pages 5481-5491.
Crossref
Crossref
Iain J McEwan. (2013) Androgen receptor modulators: a marriage of chemistry and biology. Future Medicinal Chemistry 5:10, pages 1109-1120.
Crossref
Crossref
Adam P. Dicker, Leonard G. Gomella & William Kevin Kelly. (2013) Introduction: The Changing Landscape of Prostate Cancer. Seminars in Oncology 40:3, pages 241-243.
Crossref
Crossref
BARBORA FIALOVA, KATERINA SMESNY TRTKOVA, LENKA PASKOVA, KATERINA LANGOVA & ZDENEK KOLAR. (2013) Effect of histone deacetylase and DNA methyltransferase inhibitors on the expression of the androgen receptor gene in androgen-independent prostate cancer cell lines. Oncology Reports 29:5, pages 2039-2045.
Crossref
Crossref
Dana Rathkopf & Howard I. Scher. (2013) Androgen Receptor Antagonists in Castration-Resistant Prostate Cancer. The Cancer Journal 19:1, pages 43-49.
Crossref
Crossref
Lee B. Smith, Rod T. Mitchell & Iain J. McEwanLee B. Smith & Iain J. McEwan. 2013. Testosterone: From Basic Research to Clinical Applications. Testosterone: From Basic Research to Clinical Applications
37
57
.
Michael A. Augello, William F. OstranderJr.Jr. & Karen E. Knudsen. 2013. Prostate Cancer. Prostate Cancer
461
477
.
Rui Li, Kristen Evaul, Kamalesh K. Sharma, Kai-Hsiung Chang, Jennifer Yoshimoto, Jiayan Liu, Richard J. Auchus & Nima Sharifi. (2012) Abiraterone Inhibits 3β-Hydroxysteroid Dehydrogenase: A Rationale for Increasing Drug Exposure in Castration-Resistant Prostate Cancer. Clinical Cancer Research 18:13, pages 3571-3579.
Crossref
Crossref
Tanya Stoyanova, Busola Ruth Alabi & Shiqin Liu. (2022) Current and Emerging Therapies for Neuroendocrine Prostate Cancer. SSRN Electronic Journal.
Crossref
Crossref